0.5679

3.77% -0.0221

Adaptimmune Therapeutics Plc Adr (ADAP)

Overview News Price History Option Chain Financials Discussions Forecast

Adaptimmune Therapeutics Plc Adr stock is traded at $0.5679, with a volume of 1.81M. It is down -3.77% in the last 24 hours and down -21.22% over the past month. Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

Previous Close:

$0.59

Open:

$0.58

24h Volume:

1.81M

Relative Volume:

0.94

Market Cap:

$146.83M

Revenue:

$175.04M

Net Income/Loss:

$-44.52M

P/E Ratio:

-1.0639

EPS:

-0.5338

Net Cash Flow:

$-56.05M

1W Performance:

-3.44%

1M Performance:

-21.22%

6M Performance:

-41.76%

1Y Performance:

-28.40%

1-Day Range:

$0.5582

$0.5882

1-Week Range:

$0.5473

$0.6078

52-Week Range:

$0.5473

$2.05

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Name

Adaptimmune Therapeutics Plc Adr

Sector

Healthcare (1197)

Industry

Biotechnology (670)

Phone

44 1235 430000

Address

60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE

Employee

449

Twitter

@Adaptimmune

Next Earnings Date

2024-12-13

Latest SEC Filings

ADAP's Discussions on Twitter

Compare ADAP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADAP Adaptimmune Therapeutics Plc Adr	0.5678	146.83M	175.04M	-44.52M	-56.05M	-0.18
VRTX Vertex Pharmaceuticals Inc	400.39	103.35B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	704.87	77.35B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	624.68	37.04B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	236.06	30.14B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	112.00	26.97B	3.30B	-501.07M	1.03B	-2.1146

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-24	Initiated	H.C. Wainwright	Buy
May-30-24	Initiated	Scotiabank	Sector Outperform
Mar-24-23	Initiated	Bryan Garnier	Buy
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy
Nov-09-22	Upgrade	Mizuho	Neutral → Buy
May-28-21	Initiated	Barclays	Underweight
Apr-22-20	Initiated	Mizuho	Neutral
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform
Feb-25-16	Initiated	Citigroup	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	Leerink Partners	Outperform

View All

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Latest News

Dec 23, 2024

AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register

Dec 23, 2024

These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock ‎Is - Stocks Register

Dec 23, 2024

What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register

Dec 23, 2024

Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register

Dec 23, 2024

Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register

Dec 23, 2024

Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register

Dec 23, 2024

Dec 16, 2024

Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com

Dec 16, 2024

Dec 04, 2024

Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com

Dec 04, 2024

Dec 02, 2024

Royal Dutch Shell Plc ADR (SHEL-N) QuotePress Release - The Globe and Mail

Dec 02, 2024

Nov 27, 2024

Mizuho lowers Adaptimmune price target by 50%, citing pipeline shifts and cost cuts - Investing.com

Nov 27, 2024

Nov 18, 2024

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register

Nov 18, 2024

Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register

Nov 18, 2024

Nov 14, 2024

Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa

Nov 14, 2024

Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com

Nov 14, 2024

Nov 05, 2024

ADAPAdaptimmune Therapeutics plc American Depositary Shares Latest Stock News & Market Updates - StockTitan

Nov 05, 2024

Nov 01, 2024

Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 16, 2024

Oct 14, 2024

Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024

Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News

Oct 14, 2024

Oct 10, 2024

Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily

Oct 10, 2024

Oct 09, 2024

The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle

Oct 09, 2024

Oct 08, 2024

Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News

Oct 08, 2024

Oct 07, 2024